Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

摘要: Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients harboring activating (EGFR) mutations. Nowadays, tumor tissues acquired by surgery or biopsy the routine materials EGFR mutation analysis. However, accessibility is not always satisfactory in NSCLC. Moreover, a high proportion NSCLC will eventually develop resistance to EGFR-TKIs. Invasive procedures, such as biopsy, impractical be performed repeatedly assess evolution EGFR-TKI resistance. Thus, exploring some convenient and less invasive techniques monitor treatment urgently needed. Circulating cell-free DNA (ctDNA) has degree specificity detect mutations Besides, ctDNA capable monitoring disease progression during treatment. Certain serum microRNAs that correlate with signaling pathway, miR-21 miR-10b, have been demonstrated helpful evaluating efficiency therapeutics. A commercialized serum-based proteomic test, named VeriStrat shown an outstanding ability predict clinical outcome receiving Analysis circulating cells (CTCs) feasible, CTCs represent promising material EGFR-TKI-treatment efficacy These evidences suggested non-invasive based on plasma samples had great potential In this review, we summarized these approaches considered their possible applications monitoring.